<DOC>
	<DOCNO>NCT01503905</DOCNO>
	<brief_summary>The current study multicentre , randomize , open ( unblended ) , prospective clinical trial sponsor researcher . The trial design compare effectiveness docetaxel plus epirubicin , docetaxel plus epirubicin plus cyclophosphamide neoadjuvant chemotherapy operable premenopausal breast cancer patient , also compare outcomes associate chemo-induced amenorrhea two neoadjuvant chemotherapy . The investigator randomly assign 600 premenopausal female patient operable breast cancer receive four cycle docetaxel epirubicin ( TE ) ; four cycle docetaxel , epirubicin , cyclophosphamide ( TEC ) . After every two cycle neoadjuvant chemotherapy , investigator estimate effectiveness therapy . Patients undergo modify radical mastectomy breast-conserving surgery four cycle neoadjuvant chemotherapy , receive postoperative chemotherapy ( two cycle ) , radiation therapy , herceptin target therapy hormone therapy accord NCCN ( 2011 ) guideline . The follow-up ten year surgery . The primary aim examine whether docetaxel epirubicin ( TE ) effective docetaxel , epirubicin , cyclophosphamide ( TEC ) ( pCR rate , cCR rate , PR rate , SD rate , progression-free survival ( PFS ) overall survival ( OS ) ) . The secondary aim correlate chemo ( TE/TEC ) -induced amenorrhea outcome premenopausal woman .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Operable Premenopausal Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . The patient sign write informed consent . 2 . The patient present operable breast cancer diagnose histopathology distant metastasis . 3 . The patient history anticancer therapy include chemotherapy , radiation therapy , hormone therapy surgical therapy . 4 . The patient normal cardiac function echocardiography . 5 . The patient ' ECOG score ≤ 02 . 6 . The age patient ≥ 18 year old ; And patient premenopausal female . 7 . The patient disposed practice contraception whole trial . 8 . The result patient ' blood test follow : Hb ≥ 90 g/L WBC ≥ 4.0×109/L Plt ≥ 100×109/L Neutrophils ≥ 1.5×109/L ALT AST ≤ triple normal upper limit . TBIL ≤ 1.5 time normal upper limit . Creatinine ≤ 1.25 time normal upper limit . 1 . The patient cancer time history cancer recent five year , exclude control skin basal cell carcinoma skin squamous cell carcinoma carcinoma situ cervix . 2 . The patient active infection suitable chemotherapy . 3 . The patient severe noncancerous disease . 4 . The patient undergoing current administration anticancer therapy , attend clinical trail . 5 . The patient whose breast cancer HER2 positive choose undergo neoadjuvant chemotherapy include herceptin regimen . 6 . The patient pregnant lactational , refuse practice contraception whole trial . 7 . The patient special condition ca n't understand write informed consent , demented hawkish . 8 . The patient allergic history chemotherapeutic agent . 9 . The patient bilateral breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>amenorrhea</keyword>
</DOC>